Author:
Hayes K.N.,Ban J.K.,Athanasiadis G.,Burden A.M.,Cadarette S.M.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference38 articles.
1. Cadarette SM, Carney G, Baek D, Gunrai N, Paterson JM, Dormuth CR (2012) Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int 23:1475–1480.
https://doi.org/10.1007/s00198-011-1771-2
2. Burden AM, Tadrous M, Calzavara A, Cadarette SM (2015) Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int 26:1525–1533.
https://doi.org/10.1007/s00198-014-3023-8
3. Drug Programs Policy and Strategy Branch, Ontario Public Drug Programs,Ministry of Health and Long-Term Care (2018) Ontario drug benefit formulary/comparative drug index, Edition 43.
http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/edition_43.pdf
. Accessed 23 July 2018
4. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, for the Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873.
https://doi.org/10.1503/cmaj.100771
5. Jandoc R, Mamdani M, Levesque LE, Cadarette SM (2016) Urban–rural differences in the uptake of new oral bisphosphonate formulations. Arch Osteoporosis 11(11).
https://doi.org/10.1007/s11657-016-0261-8
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献